“Getting off the Bus Closer to Your Destination”: Patients’ Views about Pharmacogenetic Testing | Zendy

Susan Brown Trinidad | Zendy; Tara B. Coffin | Zendy; Stephanie M. Fullerton | Zendy; James D. Ralston | Zendy; Gail P. Jarvik | Zendy; Eric B. Larson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

“Getting off the Bus Closer to Your Destination”: Patients’ Views about Pharmacogenetic Testing

Author(s) -

Susan Brown Trinidad,

Tara B. Coffin,

Stephanie M. Fullerton,

James D. Ralston,

Gail P. Jarvik,

Eric B. Larson

Publication year - 2015

Publication title -

the permanente journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.445

H-Index - 30

eISSN - 1552-5775

pISSN - 1552-5767

DOI - 10.7812/tpp/15-046

Subject(s) - medicine , denial , focus group , pharmacogenetics , carbamazepine , focus (optics) , medical diagnosis , psychiatry , family medicine , psychotherapist , psychology , pathology , epilepsy , genetics , gene , physics , marketing , biology , genotype , optics , business

The authors conducted focus groups with patients prescribed antidepressants (pilot session plus 2 focus groups, n = 27); patients prescribed carbamazepine (2 focus groups, n = 17); and healthy patients (2 focus groups, n = 17). Although participants understood the potential advantages of pharmacogenetic testing, many felt that the risks (discrimination, stigmatization, physician overreliance on genomic results, and denial of certain medications) may outweigh the benefits. These concerns were shared across groups but were more strongly expressed among participants with chronic mental health diagnoses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research